Company & Sponsor Intelligence
Corcept Therapeutics
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
depression
Indexed studies
NCT00128479A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
depression · United StatesPHASE3
depression · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →